Zydus gets approval from USFDA for Triamterene and Hydrochlorothiazide Tablets

02 Jul 2018 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Triamterene and Hydrochlorothiazide Tablets USP in strengths of 37.5 mg/25 mg and 75 mg/50 mg. It is used for the treatment of high blood pressure. This combination drug is used by patients who have developed or are at risk for having low potassium levels on hydrochlorothiazide. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group now has more than 195 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

963.50 15.60 (1.65%)
29-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1521.95
Dr. Reddys Lab 6279.95
Cipla 1407.55
Zydus Lifesciences 963.50
Lupin 1640.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.